521 related articles for article (PubMed ID: 32541753)
1. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature.
Kanwar N; Bakr MM; Meer M; Siddiqi A
Br Dent J; 2020 Jun; 228(11):886-892. PubMed ID: 32541753
[TBL] [Abstract][Full Text] [Related]
2. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan.
Kunihara T; Tohmori H; Tsukamoto M; Kobayashi M; Okumura T; Teramoto H; Hamasaki T; Yamasaki T; Nakagawa T; Okimoto N; Fujiwara S
Osteoporos Int; 2023 Jun; 34(6):1101-1109. PubMed ID: 37002373
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
4. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
5. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
6. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
7. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
8. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
[TBL] [Abstract][Full Text] [Related]
10. Update MRONJ and perspectives of its treatment.
Voss PJ; Poxleitner P; Schmelzeisen R; Stricker A; Semper-Hogg W
J Stomatol Oral Maxillofac Surg; 2017 Sep; 118(4):232-235. PubMed ID: 28697987
[TBL] [Abstract][Full Text] [Related]
11. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update.
Ruggiero SL; Dodson TB; Aghaloo T; Carlson ER; Ward BB; Kademani D
J Oral Maxillofac Surg; 2022 May; 80(5):920-943. PubMed ID: 35300956
[TBL] [Abstract][Full Text] [Related]
12. Management of Medication-Related Osteonecrosis of the Jaw.
Williams WB; O'Ryan F
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):517-25. PubMed ID: 26515735
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw.
Ruggiero SL
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):479-87. PubMed ID: 26293329
[TBL] [Abstract][Full Text] [Related]
14. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
15. Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.
Acharya S; Patil V; Ravindranath V; Kudva A; Nikhil K
J Med Life; 2022 Mar; 15(3):368-373. PubMed ID: 35449990
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of metastatic cancer presenting in osteonecrosis of the jaws (MC-ONJ) in patients undergoing antiresorptive and/or antiangiogenic therapy for skeletal-related adverse events.
Sacco R; Woolley J; Yates J; Calasans-Maia MD; Akintola O; Patel V
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Jun; 131(6):650-659. PubMed ID: 33518491
[TBL] [Abstract][Full Text] [Related]
17. "Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review.
Khominsky A; Lim M
Aust Dent J; 2018 Dec; 63(4):441-454. PubMed ID: 30144095
[TBL] [Abstract][Full Text] [Related]
18. The role of illicit drugs in developing medication-related osteonecrosis (MRONJ): a systematic review.
Sacco R; Ball R; Barry E; Akintola O
Br J Oral Maxillofac Surg; 2021 May; 59(4):398-406. PubMed ID: 33789811
[TBL] [Abstract][Full Text] [Related]
19. [Bisphosphonate-related osteonecrosis of the jaw-after a decade has passed].
Yoneda T
Clin Calcium; 2014 Mar; 24(3):407-15. PubMed ID: 24576938
[TBL] [Abstract][Full Text] [Related]
20. [Bisphosphonate-related osteonecrosis of the jaws].
Sogacheva VV; Syomkin VA
Stomatologiia (Mosk); 2022; 101(6):85-90. PubMed ID: 36562373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]